Deals
Financing
• Ailomics Therapeutics, a pharmaceutical R&D startup founded in 2022, announced that it raised tens of millions of RMB in the angel round led by Qiming Venture Partners. The firm plans to use the fresh funds to build core technology platform and advance R&D pipeline.
• Koutech, an ultra-micro and high-precision surgical robot platform company, raised hundreds of millions of RMB in series A funding led by Qiming Venture Partners. The funding will support R&D, team building, GMP plant construction, etc.
Portfolio Highlights
Milestones
• Dr. Xuefeng Yu, Co-Founder, CEO and Chairman of CanSino Biologics (SEHK:6185, SHSE:688185) talked exclusively with Bloomberg on the new Convidecia Air™ and its development process, discussing the world's first inhaled Covid vaccine approved for use.
• China's NMPA has officially approved ripertamab injection, the novel anti-CD20 mAb developed by SinocellTech (SHSE: 688520), to be used in combination with standard CHOP chemotherapy in adult patients with newly diagnosed CD20-positive diffuse large B-cell non-Hodgkin lymphoma (DLBCL) with an International Prognostic Index (IPI) of 0 to 2.
• CanSino Biologics (SEHK:6185, SHSE:688185) announced that China's NMPA has granted approval for its Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air™) to be used as a booster dose.
• Insta360 recently launched X3, a powerful 360 action camera that helps capture creative and unique content for social media, powered by 1/2″ 48MP sensors and 2.29″ touchscreen.
• Roborock (SHSE: 688169), ranks first among robot vacuum makers globally in terms of sales of high-end models for 12 months from July 2021 to June 2022, according to Euromonitor. Roborock also launched its latest A10 series in China.
• Bondent Group recently presented Semorr Naked Eye 3D Microscope, Semorr G4 Microscope, UDG Platinum VEU Files, as well as Wismy Endo Motor at the European Society of Endodontology (ESE).
• Global leading open metaverse platform BUD launched a crossover collaboration with NetEase Games' iconic game Never After, providing customized crossover Avatars and various theme activities for BUD users.
• Antengene (SEHK: 6996) announced that ATG-101, the company's in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer.
• OriCell Therapeutics has formally received an implied license from China's NMPA for its Ori-C101 Investigational New Drug application.
• Global leading biopharmaceutical company Zai Lab (NASDAQ:ZLAB, SEHK:9688) and Seagen, a world leader and pioneer in antibody-drug conjugate (ADC) therapies announced a strategic partnership and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan.
Awards
• 2022 Fortune China Best Designs List - UBTECH Robotics, Mech-Mind Robotics, NEIWAI
• Forbes China Global 100 Outstanding Chinese list - Wang Xiang, Partner and President of Xiaomi Technology (SEHK:1810), Song Mingyang, CEO of International Business at Meitu (SEHK:1357)
• Hong Kong Business Technology Excellence Awards 2022 in the AI - Pharmaceuticals category - Insilico Medicine
• 2022 PharmaVoice 100 List - Raymond Stevens, CEO and Founder of Structure Therapeutics, and Samantha Du, Chairperson and Chief Executive Officer of Zai Lab (NASDAQ:ZLAB, SEHK:9688)
• TOP 100 China Pharmaceutical Innovative Enterprises by Healthcare Executive - Zai Lab (NASDAQ:ZLAB, SEHK:9688), SinocellTech (SHSE: 688520), Antengene (SEHK:6996), Jacobio Pharma (SEHK:1167), CanSino Biologics (SEHK:6185, SHSE:688185), InventisBio (SHSE: 688382), Genor BioPharma (SEHK:6998), Abbisko Therapeutics (SEHK:2256), Asieris Pharmaceuticals (SHSE: 688176), ACEA Therapeutics
• TOP 100 China Pharmaceutical Innovative Emerging Enterprises by Healthcare Executive - LaNova Medicines, Suzhou Abogen Biosciences, Shenogen Pharma, Connect Biopharma (NASDAQ: CNTB), Newsoara, Kechow Pharma, Arkbio
• China's Home Market TOP 10 Best Return Star Cases of 2022 Investment Institution Series Lists by 36Kr - Tigermed (SZSE:300347, SEHK:3347)
Qiming Updates
Insights
• “We have witnessed a lot of investments in drug discovery, diagnostics, devices, tech, and so forth. There are still a lot of opportunities when investing in the infrastructure of companies,” said Nisa Leung, Managing Partner of Qiming Venture Partners, at the sidelines of the HKEX Biotech Summit on Bloomberg.
Events
• Grace Lee, Partner and the Group COO of Qiming Venture Partners, will participate in the 35th Annual Asian Venture Capital Journal Forum among other leading expert speakers. They will share expertise in deal sourcing, fundraising, the buyout and secondaries markets, exits, ESG, and more.
Awards
• 2021 Leader of the Year in the Commerce & Industry/Finance category by Sing Tao News Corporation Limited - Nisa Leung
• 2022 Yicai Equity Investment Value List - TOP 50 Investment Institution; Outstanding Female Investor - Nisa Leung
• Global Venture Capitalists 2022 Half-Year Report - TOP 4 Investment Institution Founded in China, and 24th globally
• 21st Century Private Equity and Venture Capital Competitiveness Study and Ranking by 21st Century Business Herald - TOP 30 VC and PE Institutions
• The 2021-2022 China PE/VC Industry Awards - TOP 20 China's Venture Capital Institutions, TOP 10 ESG Institutions in China's Equity Investment Industry, TOP 20 Active Investment Institutions in China's Healthcare Industry, TOP 20 Active Investment Institutions in the Artificial Intelligence Industry, TOP 20 Active Investment Institutions in the Advanced Manufacturing Industry
• 2022 Investment Institution Series Lists by 36Kr - TOP 4 in China's TOP 50 Venture Capital Voted by Limited Partners; China's Home Market TOP 10 Best Return Fund - Qiming's RMB Fund I
• Cyzone - 2022 Most Admired Venture Capital Firms in China and No.1 Healthcare Industry Investment Firm; 2022 ESG Best Practice Award for China VC Firms
• Golden Investment Mid-year Prize List of CVCRI 2022 China Venture Capital Annual List - China Influence Investment Institution, China's Best Internet/Mobile Internet Investment Institution; China's Best Investment Institution in Healthcare
Sources: Qiming Venture Partners, company press releases, media reports, etc.
